Core Viewpoint - The company, Valiant Bio-B (09887), has seen its stock price increase by over 8%, currently trading at 64.75 HKD, with a transaction volume of 44.92 million HKD, following the announcement of its dual-specific antibody LBL-034 receiving Fast Track designation from the FDA for treating relapsed/refractory multiple myeloma [1]. Group 1 - Valiant Bio-B's LBL-034 is developed based on the TCE technology platform LeadsBody, featuring a unique 2:1 structure and conditional activation [1]. - The company has a comprehensive layout for next-generation tumor immunotherapy, utilizing its agonist platform, TCE platform, and ADC [1]. - Since 2015, the company has focused on "technology platform + innovative targets," covering cutting-edge areas such as immune checkpoints and multi-specific antibodies, thereby building a differentiated pipeline [1].
维立志博-B再涨超8% TCE双抗LBL-034获FDA快速通道资格认定